{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-018802","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.238243+00:00","generated_at":"2026-06-03T05:27:55.760072+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA approves Libervant for seizure clusters in children 2-5; Anaphylm NDA on track for end of 2024","bullets":["Libervant is first FDA-approved oral rescue treatment for seizure clusters in patients ages 2-5.","Immediate availability of 5mg, 7.5mg, 10mg, 12.5mg, and 15mg; non-Medicaid prescriptions being filled.","Over 55,000 prescriptions filled in 2023 for this age group, 90% for diazepam rectal gel.","Anaphylm clinical program on track; NDA submission planned by end of 2024.","This is the Company's 4th FDA approval since 2018."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-018802","json":"https://secwatch.observer/filing/0001628280-24-018802.json","markdown":"https://secwatch.observer/filing/0001628280-24-018802.md","text":"https://secwatch.observer/filing/0001628280-24-018802.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024018802/0001628280-24-018802-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024018802/aqst-20240426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:27:55.760072+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}